SCHEMBL30714628

SCHEMBL30714628

Cn1nc2ccc(OCc3ccccc3F)cc2c1C(=O)NC1(CO)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 3/20 0.40
PARP10 Q53GL7 3/20 0.40
MAOB P27338 4/20 0.40
ADAM17 P78536 5/20 0.38
MMP13 P45452 1/20 0.38
KCNH2 Q12809 1/20 0.38
RARA P10276 1/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
GCK P35557 1/20 0.38
NPC1 O15118 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MET P08581 1/20 0.38
PARP14 Q460N5 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714753 0.96 PARP15 (0.39) PARP15PARP10MAOBADAM17MMP13
SCHEMBL30714736 0.94 ADAM17 (0.43) PARP15PARP10MAOBADAM17MMP13
SCHEMBL31539884 0.88 MAOB (0.39) PARP15PARP10MAOBMMP13KCNH2
SCHEMBL30714748 0.87 HTR3A (0.43) ADAM17MMP13SMN1; SMN2MEN1KMT2A
SCHEMBL30714680 0.85 SCN9A (0.38) ADAM17MMP13
SCHEMBL30714755 0.85 PARP15 (0.41) PARP15PARP10MAOBADAM17MMP13
SCHEMBL30714644 0.85 SMO (0.40) PARP10KCNH2MET
SCHEMBL30714724 0.83 MMP13 (0.45) PARP15PARP10MAOBADAM17MMP13
SCHEMBL26869341 0.83 PARP15 (0.42) PARP15PARP10MAOBKCNH2RARA
SCHEMBL26696061 0.82 PARP10 (0.47) PARP15PARP10MAOBKCNH2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 PARP15 1331/4885PARP10 1863/4885MAOB 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.